S&P 500 falls after giving up gains as Oracle slump weighs on tech
Bio Key International NASDAQ:BKYI Chief Executive Officer Michael DePasquale reported purchasing shares of the company’s stock in two transactions on September 15 and 16, 2025. The micro-cap company, currently valued at $5.28 million, has seen its stock surge 10% in the past week, despite trading significantly below its 52-week high of $3.68. The total value of the purchases amounted to $3233, with prices ranging from $0.75 to $0.84.
On September 15, DePasquale acquired 2,500 shares at $0.75 per share. The following day, September 16, he purchased an additional 1,617 shares at $0.84 per share. Following these transactions, DePasquale directly owns 102,775 shares of Bio Key International.
In other recent news, BIO-key International Inc. reported a substantial 49% increase in revenue for the second quarter of 2025 compared to the same period last year. This notable financial performance highlights the company’s growth trajectory in recent months. Additionally, shareholders of BIO-key International approved all proposals presented at the company’s annual meeting. Five directors, including Michael W. DePasquale and Wong Kwok Fong (Kelvin), were elected to serve one-year terms on the board. The vote totals for these nominees ranged from 995,776 to 1,001,229 in favor, with 299,168 to 304,621 votes withheld. These developments underscore significant corporate governance activities within the company. Despite the positive financial results, the company’s stock experienced a decline, attributed to investor concerns over broader market conditions and future guidance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.